Vitiligo-associated multiple autoimmune disease susceptibility 1

Overview

What is Vitiligo-associated multiple autoimmune disease susceptibility 1?

Vitiligo is an autoimmune disease characterized by melanocyte loss (losing pigmentation of the skin and hair), which results in a patchy appearance of the skin and hair. It is associated with an elevated risk of other autoimmune diseases. Vitiligo is a genetically complex disorder that involves multiple genes that can make somebody more susceptible to this disorder if they carry changes in these genes. Vitiligo is also associated with unknown environmental triggers. People with vitiligo have elevated frequencies of other autoimmune diseases, suggesting that these diseases involve shared genetic components.

References
Show More Content Like This

More Overview Content

What else is Vitiligo-associated multiple autoimmune disease susceptibility 1 called?

How many people have Vitiligo-associated multiple autoimmune disease susceptibility 1?

What health problems are part of Vitiligo-associated multiple autoimmune disease susceptibility 1?

What else is Vitiligo-associated multiple autoimmune disease susceptibility 1 called?

This disorder may also be called:

  • Vitiligo
  • VTLG Systemic Lupus Erythematosus
  • Vitiligo-Related
  • SLEV1
  • VAMAS1
References
How many people have Vitiligo-associated multiple autoimmune disease susceptibility 1?

Vitiligo affects approximately 0.5 to 1 percent of the population worldwide. This condition may be more noticeable in dark-skinned people, but occurs equally in all ethnic groups.

What health problems are part of Vitiligo-associated multiple autoimmune disease susceptibility 1?

In general, Vitiligo-associated multiple autoimmune disease susceptibility 1 can cause autoimmune problems and skin pigmentation changes. More specific symptoms can be found under the "Symptoms" section.

References
  • https://www.mendelian.co/vitiligo-associated-multiple-autoimmune-disease-susceptibility-1-vamas1

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more about our use of cookies and similar technology

This content comes from a hidden element on this page.

The inline option preserves bound JavaScript events and changes, and it puts the content back where it came from when it is closed.

Remember Me